Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment.

about

Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment.

Item

http://www.wikidata.org/entity/Q35634785

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Prognostic factors of resected ...... ses, and multimodal treatment.

@ast

Prognostic factors of resected ...... ses, and multimodal treatment.

@en

type

Item

label

Prognostic factors of resected ...... ses, and multimodal treatment.

@ast

Prognostic factors of resected ...... ses, and multimodal treatment.

@en

prefLabel

Prognostic factors of resected ...... ses, and multimodal treatment.

@ast

Prognostic factors of resected ...... ses, and multimodal treatment.

@en

P1476

Prognostic factors of resected ...... ses, and multimodal treatment.

@en

P2093

Alessandro Marra

http://www.w3.org/2001/XMLSchema#string

Gunther Richardsen

http://www.w3.org/2001/XMLSchema#string

Ludger Hillejan

http://www.w3.org/2001/XMLSchema#string

Olaf M Koch

http://www.w3.org/2001/XMLSchema#string

Wolfgang Wagner

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Revisions in the International System for Staging Lung Cancer

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.

Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Induction treatment before surgery for non-small cell lung cancer.

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.

P304

Doc01

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3205/TSS000021

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Müller-Tidow

P577

2011-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51970109

http://www.w3.org/2001/XMLSchema#string

P698

22205919

http://www.w3.org/2001/XMLSchema#string

P932

3246278

http://www.w3.org/2001/XMLSchema#string